Last reviewed · How we verify
budesonide bid + terbutaline 'as needed'
budesonide bid + terbutaline 'as needed' is a Inhaled corticosteroid + short-acting beta-2 agonist combination Small molecule drug developed by AstraZeneca. It is currently in Phase 3 development for Asthma maintenance and rescue therapy, Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction.
Budesonide reduces airway inflammation via glucocorticoid receptor activation, while terbutaline rapidly relaxes airway smooth muscle via beta-2 adrenergic stimulation.
Budesonide reduces airway inflammation via glucocorticoid receptor activation, while terbutaline rapidly relaxes airway smooth muscle via beta-2 adrenergic stimulation. Used for Asthma maintenance and rescue therapy, Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction.
At a glance
| Generic name | budesonide bid + terbutaline 'as needed' |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Inhaled corticosteroid + short-acting beta-2 agonist combination |
| Target | Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (terbutaline) |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
Budesonide is an inhaled corticosteroid that suppresses inflammatory cytokines and immune cell recruitment in the airways, providing sustained anti-inflammatory control. Terbutaline is a short-acting beta-2 agonist that activates beta-2 adrenergic receptors on bronchial smooth muscle, causing rapid bronchodilation for acute symptom relief. This combination provides both maintenance anti-inflammatory therapy and rescue bronchodilation.
Approved indications
- Asthma maintenance and rescue therapy
- Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction
Common side effects
- Tremor
- Headache
- Nervousness/anxiety
- Palpitations
- Oral candidiasis
- Dysphonia
- Muscle cramps
Key clinical trials
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma (PHASE3)
- A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma. (PHASE3)
- Prn Budesonide/Formoterol Versus Regular Budesonide/Formoterol Plus Prn Terbutaline in Mild-Moderate Asthma (PHASE3)
- Study to Investigate the Efficacy of Symbicort® SMART. (PHASE3)
- A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma (PHASE3)
- Comparison of the Efficacy/Safety of Symbicort® Turbuhaler®,Seretide™ Diskus™ 50/500 µg & Terbutaline Turbuhaler® 0.4 mg (PHASE3)
- Prevention of Asthma Relapse After Discharge From Emergency (PHASE3)
- DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- budesonide bid + terbutaline 'as needed' CI brief — competitive landscape report
- budesonide bid + terbutaline 'as needed' updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about budesonide bid + terbutaline 'as needed'
What is budesonide bid + terbutaline 'as needed'?
How does budesonide bid + terbutaline 'as needed' work?
What is budesonide bid + terbutaline 'as needed' used for?
Who makes budesonide bid + terbutaline 'as needed'?
What drug class is budesonide bid + terbutaline 'as needed' in?
What development phase is budesonide bid + terbutaline 'as needed' in?
What are the side effects of budesonide bid + terbutaline 'as needed'?
What does budesonide bid + terbutaline 'as needed' target?
Related
- Drug class: All Inhaled corticosteroid + short-acting beta-2 agonist combination drugs
- Target: All drugs targeting Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (terbutaline)
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Respiratory / Pulmonology
- Indication: Drugs for Asthma maintenance and rescue therapy
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) with reversible airflow obstruction
- Compare: budesonide bid + terbutaline 'as needed' vs similar drugs
- Pricing: budesonide bid + terbutaline 'as needed' cost, discount & access